20 articles
In obese middle-aged mice, reducing dietary protein—without cutting calories—reversed cardiac inflammation and remodeling via AMPK-ULK1 mitophagy.
A transcription factor in endothelial cells declines with age and its loss drives fibrosis, hypertrophy, and diastolic dysfunction — but restoring it reverses damage.
A novel CTSL–Notch1–CUX1 pathway drives endothelial senescence and atherosclerotic plaque buildup, revealing fresh drug targets.
Scientists reveal CFTR protein prevents cardiomyocyte senescence by reducing mitochondrial oxidative stress via a newly discovered deubiquitination pathway.
A newly discovered protein called HELZ2 controls how much harmful cholesterol the liver releases, opening a fresh path to heart disease treatment.
Deleting CPT1a in mouse livers dramatically lowers ApoB-containing lipoproteins by accelerating clearance, revealing a new lipid metabolism target.
New research reveals how eliminating urokinase plasminogen activator can temporarily protect against diet-induced weight gain and metabolic dysfunction.
New research reveals how genetic variants in PCSK9 dramatically reduce cardiovascular disease risk through improved cholesterol metabolism.
New research reveals how GRK2 protein clumping damages brain cells and identifies potential therapeutic targets to slow cognitive decline.
New research reveals specific proteins that explain why lower socioeconomic status increases cardiovascular disease risk in older adults.
A forward genetic screen in mice reveals HELZ2 helicase degrades APOB mRNA, linking RNA stability to fatty liver disease and heart disease risk.
New research shows GDF11, an anti-aging protein, prevents dangerous calcium buildup in arteries by suppressing inflammatory pathways.
Natural isoflavone prevents cardiac enlargement through novel mitochondrial protection pathway, offering new therapeutic approach.
A 330-patient multicenter RCT tests whether thymosin α1 can curb immune dysregulation and organ dysfunction after acute type A aortic dissection repair.
Scientists map a precise molecular chain linking falling NAD levels to lysosomal dysfunction, cardiolipin loss, and age-related heart failure — and show NAD restoration can reverse it.
New drugs can achieve extremely low LDL levels similar to genetic mutations linked to exceptional longevity, without apparent safety concerns.
New JAMA research suggests ApoB may outperform standard lipid panels for detecting CVD risk in younger populations.
A 2025 review maps the molecular mechanisms driving cardiovascular aging—from inflammaging to ECM remodeling—and outlines emerging therapies.
New research reveals how elevated Lp(a) levels interact with hormonal changes to significantly increase venous thromboembolism risk.
New review reveals how telomere shortening drives cardiovascular aging and identifies promising therapeutic targets for heart health.
